Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07495852 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
A Phase 3 study, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT07495852: Recruiting Phase 3 study, sponsored by Glaukos Corporation.
NCT07495852 is a Phase 3 study that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 510 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07495852, a Phase 3 study, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Primary Outcome
Change from baseline in diurnal IOP in the study eye at 8am and 10am at each of Day 11, Week 6, and Month 3 visits
Interventions
- PROCEDURE Sham Procedure
- DRUG Gen 2 Travoprost Intracameral Implant
- DRUG Timolol eye drops 0.5%
- OTHER placebo eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2032-03 |
| Phase | Phase 3 |
What NCT07495852 shows while recruiting
NCT07495852 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 4 interventions - of which Sham Procedure is the first listed.
NCT07495852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07495852 about?
NCT07495852 is a clinical study titled "Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant". Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
What is the current status of trial NCT07495852?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2026-02-17. Estimated completion is 2032-03.
What interventions are being tested in trial NCT07495852?
The interventions under investigation include: Sham Procedure (PROCEDURE), Gen 2 Travoprost Intracameral Implant (DRUG), Timolol eye drops 0.5% (DRUG), placebo eye drops (OTHER).
Who is sponsoring clinical trial NCT07495852?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07495852's enrollment target sits among peer trials
510 729th of 2000 higher than 1,264 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI